

Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa

NCT05285917

Status	RECRUITING
Phase	Phase 3
Sponsor	Brown University
Enrollment	400 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of sickle cell anemia (HbSS or HbS/B0-thalassemia)
- Age 6 months- 12 years of age at enrollment
- Parent or guardian willing and able to provide written or informed consent
- Weight ≥ 7.5 kg (temporary exclusion)

Exclusion (5)

- Splenomegaly with evidence of hypersplenism as defined by platelet count $< 150,000$, hemoglobin < 5 g/dL or absolute neutrophil count $< 1.0 \times 10^9/L$
- Hydroxyurea use within the past 6 months
- Blood transfusion within the past 6 months (temporary exclusion)
- Pregnancy
- Pre-existing severe hematologic toxicity, as defined by platelet count $< 80,000$, hemoglobin < 4 regardless of ANC; hemoglobin < 6 AND ARC < 100 ; hemoglobin < 7 AND ARC $< 80 \times 10^9/L$ (temporary exclusion)

Locations (1 total)

Hospital Geral dos Cajueiros, Luanda, Angola